Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma

European Spine Journal

Volumn 23, Issue 11, 2014, Pages 2416-2422

  Akhavan Sigari, Reza ^a   Gaab, Michael Robert ^b   Rohde, Veit ^a   Abili, Mehdi ^c   Ostertag, Helmut ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NORDSTADT HOSPITAL   (Germany)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; INOS; Spinal chordoma; VEGFR2

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; VASCULOTROPIN RECEPTOR 2; NOS2 PROTEIN, HUMAN; TUMOR MARKER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CERVICAL SPINE; CHORDOMA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMBAR SPINE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SACRUM; SPINAL CHORDOMA; SPINE CANCER; THORACIC SPINE; TISSUE MICROARRAY; TUMOR VASCULARIZATION; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SPINAL NEOPLASMS; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHORDOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRIC OXIDE SYNTHASE TYPE II; PROGNOSIS; SPINAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84928646077     PISSN: 09406719     EISSN: 14320932     Source Type: Journal    
DOI: 10.1007/s00586-014-3417-5     Document Type: Article

References (33)

1. Al-Mefty O, Borba LA (1997) Skull base chordomas: a management challenge. J Neurosurg 86(2):182–189
2. Mendenhall WM, Mendenhall CM, Lewis SB, Villaret DB, Mendenhall NP (2005) Skull base chordoma. Head Neck 27(2):159–165
3. Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN (2006) Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59(2):230–237 (discussion 230–237)
4. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH (2007) Chordoma: the nonsarcoma primary bone tumor. Oncologist 12(11):1344–1350
5. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S (2004) Imatinib mesylate in chordoma. Cancer 101(9):2086–2097
6. Hof H, Welzel T, Debus J (2006) Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 29(12):572–574
7. Lindén O, Stenberg L, Kjellén E (2009) Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol Stockh Swed 48(1):158–159
8. Miettinen M, Rikala M-S, Rys J, Lasota J, Wang Z-F (2012) Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol 36(4):629–639
9. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M (2001) Tissue microarray: a new technology for amplification of tissue resources. Cancer J Sudbury Mass 7(1):24–31
10. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem Off J Histochem Soc 29(4):577–580
11. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol Off J Am Soc Clin Oncol 22(1):175–184
12. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology, und College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(1):118–145
13. O’Connell JX, Renard LG, Liebsch NJ, Efird JT, Munzenrider JE, Rosenberg AE (1994) Base of skull chordoma. A correlative study of histologic and clinical features of 62 cases. Cancer 74(8):2261–2267
14. Volpe R, Mazabraud A (1983) A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm). Am J Surg Pathol 7(2):161–170
15. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM (2000) Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88(9):2122–2134
16. Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Roessner A (2005) Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions. Am J Clin Pathol 124(2):288–294
17. Naka T, Boltze C, Kuester D, Schulz T-O, Samii A, Herold C, Ostertag H, Roessner A (2004) Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol 122(6):926–930
18. Naka T, Boltze C, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A (2003) Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer 98(9):1934–1941
19. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control CCC 12(1):1–11
20. Salisbury JR (1993) The pathology of the human notochord. J Pathol 171(4):253–255
21. Barry JJ, Jian BJ, Sughrue ME, Kane AJ, Mills SA, Tihan T, Parsa AT (2011) The next step: innovative molecular targeted therapies for treatment of intracranial chordoma patients. Neurosurgery 68(1):231–240 (discussion 240–241)
22. Song Z-J, Gong P, Wu Y-E (2002) Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol WJG 8(4):591–595
23. Nicotera P, Bonfoco E, Brüne B (1995) Mechanisms for nitric oxide-induced cell death: involvement of apoptosis. Adv Neuroimmunol 5(4):411–420
24. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M (1998) Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90(8):587–596
25. Akhavan-Sigari R, Gaab MR, Rohde V, Brandis A, Tezval H, Abili M, von Eckardstein K, Ostertag H (2013) Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors. Neurosurg Rev 37(1):79–88
26. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NP, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72(6):835–846
27. Minami T, Rosenberg RD, Aird WC (2001) Transforming growth factor-beta 1-mediated inhibition of the flk-1/KDR gene is mediated by a 5′-untranslated region palindromic GATA site. J Biol Chem 276(7):5395–5402
28. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncol 7(2):134–153
29. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99(11):2625–2634
30. Zhang N, Fang Z, Contag PR, Purchio AF, West DB (2004) Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 103(2):617–626
31. Hanna SA, Aston WJS, Briggs TWR, Cannon SR, Saifuddin A (2008) Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop 466(9):2217–2223
32. Wakao N, Imagama S, Ito Z, Ando K, Hirano K, Tauchi R, Muramoto A, Matsui H, Matsumoto T, Matsuyama Y, Ishiguro N (2011) Total en bloc spondylectomy for L2 chordoma: a case report. Nagoya J Med Sci 73(3–4):197–203
33. Rich TA, Schiller A, Suit HD, Mankin HJ (1985) Clinical and pathologic review of 48 cases of chordoma. Cancer 56(1):182–187